

Discovery and optimization of a novel drug candidate for
treatment of late-stage human african
trypanosomiasis

- SCYX 7158 -

Antoine TARRAL

on behalf of
Robert DON




DNDi

Drugs for Neglected Diseases *initiative*


DNDi

Drugs for Neglected Diseases *initiative*

SCYX 7158



PM = 367.11 g/mol




Chemical name: (4-Fluoro-N-(1-hydroxy-3,3-dimethyl-1,3-dihydro-benzo[c][1,2]oxaborol-6-yl)-2-trifluoromethyl benzamide)

OXABOROLE-6 BENZAMIDE

In Vitro efficacy

<i>T. brucei</i> Strain Tested	SCYX-7158
<i>T. b. brucei</i> SBRI 427*	0.267
<i>T. b. rhodesiense</i> STIB 900	0.294
<i>T. b. gambiense</i> 40R	0.363
<i>T. b. gambiense</i> 108R	0.165
<i>T. b. gambiense</i> DAL 1402	0.065
<i>T. b. gambiense</i> ITMAP 141267	0.092
<i>T. b. gambiense</i> Drani	0.129

In vivo Efficacy – Stage 2



Safety studies

Safety Pharmacology (GLP)

- Standard genotoxicity battery
 - Ames
 - In vivo micronucleus test
 - In vitro chromosomal aberration
- hERG
- Telemetry (cardiovascular) Dog
- Respiratory in Rat
- Functional Observation Battery in Rat

Toxicokinetics


Safety Pharmacology

- Standard genotoxicity battery
 - Ames Ames -ve
 - In vivo micronucleus test negative
 - In vitro chromosomal aberration negative
- hERG IC50 >100µM
- Telemetry Dog (5, 15, 40 mpk) No observations
- Respiratory in Rat (15, 40, 80 mpk) No observations
- Functional Observation Battery in Rat
 - (15, 40, 80 mpk) No observations

DMPK

- **Absorption**
 - **In vitro** MDR1-MDCK cells system High absorption potential
High distribution in brain
No significant efflux
 - **In vivo** Dog $\approx 100\%$ in dog
Monkey $\approx 80\%$
Rat , Mouse $\approx 50\%$
- **Bioavailability** **Tmax** 4.5- 9.5 H in all species
linearity dose proportional
- **Volume of distribution** : $\approx 0.6 - 0.7$ l/kg in all species
- **T_{1/2} elimination** ≈ 25 H
- **High protein binding** $\approx 95\%$ in all species

Metabolism



CYP Induction

- Inducer of CYP 2B6 and 3A4

ADME

Mass balance in rats

	Faeces	Urine	F + U	Total measured
Male	66%	20%	86%	89%
Female	73%	14%	87%	90%

Excretion after 14 days

Tissue distribution

- Well distributed in all tissues Brain Rat \approx 44% Mouse 38%
- Highest levels in liver kidney and subcutaneous fat
- Lowest levels in eye and brain 1.5 -2 fold lower than blood

Rat Toxicokinetics

Toxicokinetics

- 7 days TK in rat 50, 140, 400mg/kg
 - weight loss and loss of appetite
 - Histopathology : stress related changes
- 28 days TK in rat 5, 15, 40, 80 mg/kg
 - Loss of appetite and weight loss at 80 mg/kg
 - Main target organ RBC : ↓ RBC:9-11%, ↓Hb 9%, ↓Hct 8-10%,
↑ Reticulocyte:75- 80%
 - No signs of bleeding nor hemolysis but
- ↑ Extra medullar hematopoiesis
 - Histopath : no signs of bleeding no hemolysis ,
 - clinical chemistry: No abnormal signs
 - **NOAEL = 15 mg/kg**

DOG Toxicokinetics

Toxicokinetics

- 7 days study TK in Dog 5, 20, 50 mg/kg
 - weight loss and loss of appetite
 - Histopathology : stress related changes
 - Reduced weight of thymus and spleen
- 28 days TK in dog 5, 15, 40 mg/kg
 - Loss of appetite and weight loss (emesis) at 40 mg/kg
 - Main target findings ; decrease in food consumption
 - clinical chemistry: - 40 mg/kg/d Hb, Ht, decrease
 - 15 and 5 mg/kg: only anecdotic, ancillary variations (Haemato and BC)

NOAEL =15 mg/kg

Clinical Pathology – relevant findings(1)

Gastrointestinal tract,

1. Rat: NAD*
2. Dog: minimal dilated/cystic gland in different segments mainly at 40 mg/kg/d

Possibly relevant, present at high doses

Pancreas,

1. Rat: Acinar cell vacuolation
2. Dog: Acinar cells: decreased basophilia focal acinar cell necrosis-mild 40mg/kg

Possibly relevant

*NAD: No abnormalities detected

Clinical Pathology – relevant findings (2)

Liver:

1. Rat: Hepatocellular hypertrophy in males, Single cell necrosis in females at 40mg/kg, NAD* below.
Liver function tests are not affected
- 2 Dog: glycogen depletion in centrilobular hepatocytes and cytoplasmic rarefaction in periportal hepatocytes
Liver function tests are not affected

Relevance ?

Kidney

- 1 Rat: NAD*
- 2 Dog: Basophilic tubules, single cell necrosis: 1 male at 15 mg/kg .
-Renal function (BUN, Creatinin) not affected.

Relevance ?

*NAD: No abnormalities detected

Clinical Pathology – relevant findings (3)

Adrenals

1. Rat: Cortical hypertrophy both the sexes at 40 mg/kg
2. Dog: Cortical hypertrophy zona fasciculata: minimal to mild

Relevance: stress?

Thyroids

Dog only: follicular epithelial hypertrophy: minimal

Relevance : stress?

Testes Rat: Seminiferous tubule degeneration and epididymides (cellular debris in duct lumen) 40 mg/kg/d

Ovaries Rat: atrophy of interstitial tissue of ovaries, atrophy of uteri and vagina

Relevance : ?

Summary of DATA

- **New family of drug : OXABOROLE-6 BENZAMIDE**
- **Exhibit a high in vitro potency vs *trypanosoma Brucei***
- ***Good physicochemical properties compatible with brain penetration***
- ***Active in acute and chronic mouse model of HAT model***
- ***Good PK properties compatible with a once a day dosing***
- ***NOAEL in rat 15mg/kg in rat and dog***
- ***Human starting dose in SAD will be 20mg = 0.33 mg/kg***

Thank you